ClinicalTrials.gg
AvailableNCT07216378Updated Jul 23, 2026

Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

An expanded access record providing Sebetralstat in Hereditary Angioedema, sponsored by KalVista Pharmaceuticals, Ltd.. Available at 6 sites in United States. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by KalVista Pharmaceuticals, Ltd. (part of Chiesi Farmaceutici S.p.A.) · Expanded access

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Expanded access
Access type
Treatment IND/protocol
Ages
2 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. Angioedemas, Hereditary · Chiesi Farmaceutici S.p.A..

Other kind
2 of 12
none open now
Registered
11th of 12
by date

Among the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., this one is one of 2 of another kind, and was the 11th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

1 of the 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 2 Years to 11 Years · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Angioedemas, Hereditary by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

The sebetralstat Early Access Program (EAP) provides early access to the investigational medicinal product (IMP) sebetralstat to eligible and approved Hereditary Angioedema (HAE) pediatric (ages 2-11) post-trial and naïve patients for the on-demand treatment of angioedema attacks where the treating Physician determines they might benefit from this treatment.

03

Conditions studied

  • Hereditary Angioedema
04

Who can participate

Ages eligible
2 Years to 11 Years
Sexes eligible
All

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 2 to 11 years of age.
  • Parent or LAR provides signed and patient provides assent (when applicable).
  • Confirmed diagnosis of HAE.

Exclusion criteria

Exclusion Criteria:

  • Confirmed diagnosis of HAE with nC1-INH or acquired angioedema
  • Patient weighs \<9.5 kg
  • Patient participated in the KVD900-303 trial and withdrew prior to trial completion per the protocol or trial closure
  • Any medical condition or medical history that, in the opinion of the Treating Physician, would interfere with the patient's safety.
  • Known to sebetralstat or its .
  • Patient with a medical history or known to have severe hepatic impairment ( C).
  • Patients who require sustained use of strong cytochrome P450 3A4 inhibitors or inducers.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Access details

Study type
Expanded access
Access type
Treatment IND/protocol

Available treatment

  • Oral Plasma Kallikrein Inhibator

    Also known as: KVD900

06

Where to request access

6 of 6 sites recruiting
  • KalVista Investigative Site
    San Diego, California 92123, United States
    Available
  • KalVista Investigative Site
    Evansville, Indiana 47715, United States
    Available
  • KalVista Investigative Site
    Wheaton, Maryland 20902, United States
    Available
  • KalVista Investigative Site
    St Louis, Missouri 63110, United States
    Available
  • KalVista Investigative Site
    Knoxville, Tennessee 37909, United States
    Available
  • KalVista Investigative Site
    San Antonio, Texas 78229, United States
    Available
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT07216378
Responsible party
Sponsor
First posted
Oct 14, 2025
Last update
Jul 23, 2026

Study contacts

KalVista Pharmaceuticals Ltd
Contact
expandedaccess@kalvista.com
1 (857) 999-0075
View the source record on ClinicalTrials.gov ↗

Requesting access

Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.

Contact the provider

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion